Kaspars O.
- Country
- Latvia
- Department
- Ophthalmology
Research Overview
- A Randomized, Double-masked Study Comparing the Efficacy and Safety of AVT29 Versus High-Dose Aflibercept in Participants with Diabetic Macular Edema
- Long-Term Extension Study of Imeroprubart in Adult Patients With Graves' Disease
- Randomized, Double‑Masked, Multicenter Phase 2/3 Trial of Intravitreal MK‑8748 versus Aflibercept in Neovascular Age‑Related Macular Degeneration
Data & Insights
Has run more than one trial at 107 of 190 partner sites.
Specializations
Retinal vascular disease
Kaspars Ozols is involved in clinical research focused on diabetic macular edema, wet age-related macular degeneration, and broader chorioretinal vascular disease, with attention to therapies that address vision-threatening retinal fluid and neovascular activity.
- Diabetic macular edema
- Wet age-related macular degeneration
- Chorioretinal vascular disease
This area includes comparative evaluation of intravitreal and anti-angiogenic treatment options in retinal disease.
Neovascular age-related macular degeneration
His work also covers macular neovascularization secondary to age-related macular degeneration and related neovascular age-related macular degeneration treatment strategies, reflecting a strong interest in preserving visual function through retinal disease management.
- Macular neovascularization secondary to age-related macular degeneration
- Neovascular age-related macular degeneration
- Visual acuity preservation
The research landscape includes assessment of long-acting ophthalmic therapies for chronic macular disease.
Thyroid eye disease
Kaspars Ozols is actively engaged in studies of thyroid eye disease and Graves’ disease, with a therapeutic focus on reducing orbital inflammation and proptosis while supporting endocrine control.
- Thyroid eye disease
- Graves’ disease
- Proptosis
His clinical activity spans both ophthalmic and autoimmune endocrine manifestations of this condition.
Autoimmune endocrine ophthalmology
His trial portfolio includes investigation of thyroid eye disease-related and Graves’ disease-related therapies that target immune-mediated disease activity, including outcomes linked to thyroid hormone regulation and sustained control of ocular involvement.
- Autoimmune thyroid disease
- Thyroid-associated orbitopathy
- Endocrine-ophthalmic disease control
This area reflects involvement in treatments aimed at both ocular symptoms and systemic autoimmune drivers.
Ophthalmic therapeutic innovation
Across his research sites in Ventspils, Latvia, Kaspars Ozols contributes to ophthalmic studies evaluating emerging treatment options for retinal and orbital disease, including biosimilar and novel biologic approaches in retinal vascular disease and thyroid eye disease.
- Retinal and orbital therapeutics
- Biosimilar ophthalmic treatments
- Novel biologic therapies
His clinical interests are centered on conditions with major impact on vision and ocular structure.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.